CWM LLC purchased a new stake in shares of CervoMed Inc. (NASDAQ:CRVO - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 38,253 shares of the company's stock, valued at approximately $292,000. CWM LLC owned about 0.67% of CervoMed as of its most recent filing with the Securities & Exchange Commission.
Separately, Rock Springs Capital Management LP purchased a new position in CervoMed during the 3rd quarter worth $370,000. 25.15% of the stock is currently owned by institutional investors and hedge funds.
CervoMed Trading Down 0.3 %
Shares of NASDAQ:CRVO traded down $0.08 during trading on Friday, hitting $24.06. The stock had a trading volume of 38,332 shares, compared to its average volume of 25,832. CervoMed Inc. has a 12-month low of $4.14 and a 12-month high of $26.38. The stock has a 50-day simple moving average of $20.70 and a two-hundred day simple moving average of $13.47.
Wall Street Analysts Forecast Growth
A number of brokerages have recently weighed in on CRVO. Canaccord Genuity Group boosted their price target on CervoMed from $50.00 to $65.00 and gave the stock a "buy" rating in a research note on Monday, April 8th. Canaccord Genuity Group started coverage on shares of CervoMed in a research note on Thursday, February 15th. They set a "buy" rating and a $50.00 price target on the stock.
Get Our Latest Stock Report on CRVO
About CervoMed
(
Free Report)
CervoMed Inc, a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurogenerative diseases. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.
Further Reading
Before you consider CervoMed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CervoMed wasn't on the list.
While CervoMed currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for June 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.
Get This Free Report
